Bacterial Persisters

A bacterial gene shuts down the cell's own protein synthesis, which sends the bacterium into dormancy and allows it to outlast antibiotics.

Written byKerry Grens
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

PERSISTER PATHWAY: Phosphorylation of GltX by the bacterial toxin HipA (1) blocks GltX from adding an amino acid to transfer RNA (tRNA) (2). Uncharged tRNAs clog up the protein synthesis machinery (3), which leads to the production of the alarmone guanosine pentaphosphate [(p)ppGpp], synthesized by RelA, (4) and the subsequent shut down of cellular activities.

The paper
E. Germain et al., “The molecular mechanism of bacterial persistence by HipA,” Molecular Cell, 52:248-54, 2013.

In any given colony of, say, one million bacterial cells, there are bound to be one or two individuals that will survive an onslaught of antibiotics. The phenomenon, first identified in the 1940s, is called bacterial persistence or multidrug tolerance. Unlike antibiotic resistance, which results from a genetic alteration that renders a bacterium invulnerable to particular drugs, persistence derives from a sort of cellular sleep. Normal cellular functions shut down, giving antibiotics—which typically target active processes, such as translation or transcription—nothing to attack.

Bacteria capable of persistence have dueling protein pairs—a toxin and an antitoxin. The toxin forces the cell into a dormant state, and the antitoxin ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies